AVID-200 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase I drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AVID-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AVID-200 overview
AVID-200 is under development for the treatment of solid tumors including triple negative breast cancer, non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (SCCHN), Hhepatocellular carcinoma (HCC), microsatellite-stable colorectal carcinoma (MSS CRC), or pancreatic ductal adenocarcinoma, anemia associated with myelodysplastic syndrome, primary myelofibrosis, post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis and systemic sclerosis (scleroderma). It is administered by intravenous route. The drug candidate is an antibody-drug conjugate, computationally designed class of avidity-enhanced receptor-ectodomain-based trap that binds and neutralizes TGF-beta 1 and 3. The drug candidate was also under development for the treatment of idiopathic pulmonary fibrosis.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
For a complete picture of AVID-200’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - AVID-200 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Premium Insights
The gold standard of business intelligence.
